Canada Markets open in 8 hrs 4 mins
  • S&P/TSX

    19,222.74
    -35.58 (-0.18%)
     
  • S&P 500

    3,821.55
    -78.56 (-2.01%)
     
  • DOW

    30,946.99
    -491.27 (-1.56%)
     
  • CAD/USD

    0.7771
    +0.0001 (+0.0093%)
     
  • CRUDE OIL

    111.17
    -0.59 (-0.53%)
     
  • BTC-CAD

    26,138.89
    -764.78 (-2.84%)
     
  • CMC Crypto 200

    440.48
    -9.59 (-2.13%)
     
  • GOLD FUTURES

    1,821.80
    +0.60 (+0.03%)
     
  • RUSSELL 2000

    1,738.84
    -32.90 (-1.86%)
     
  • 10-Yr Bond

    3.2060
    0.0000 (0.00%)
     
  • NASDAQ futures

    11,715.75
    +41.50 (+0.36%)
     
  • VOLATILITY

    28.36
    +1.41 (+5.23%)
     
  • FTSE

    7,323.41
    +65.09 (+0.90%)
     
  • NIKKEI 225

    26,757.56
    -291.91 (-1.08%)
     
  • CAD/EUR

    0.7390
    +0.0009 (+0.12%)
     

Applied Therapeutics to Present at the UBS Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Applied Therapeutics
Applied Therapeutics

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate in a fireside chat at the UBS Global Healthcare Conference on Wednesday, March 25, 2022 at 10:45 a.m. ET in New York.

Webcast information for this event will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at www.appliedtherapeutics.com. A replay will also be available following the webcast.

About Applied Therapeutics

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, AT-007, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy, as well as novel dual PI3k inhibitors in preclinical development for orphan oncology indications.

To learn more, please visit www.appliedtherapeutics.com and follow the company on Twitter @Applied_Tx.

Contacts

Investors:
Maeve Conneighton
(212) 600-1902 or
appliedtherapeutics@argotpartners.com

Media:
media@appliedtherapeutics.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting